NCT02200094已完成不适用
Micardis®. Observational Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 4,532
- 主要终点
- Global evaluation of treatment compliance by investigator, a 6-point rating scale
研究概览
简要总结
This study is designed to supplement, under conditions of usual clinical practice, the data on the efficacy and safety of Micardis® collected during the clinical studies.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of either sex over the age of 18 years suffering from essential hypertension requiring treatment according to the physician
排除标准
- •Hypersensitivity to the active component or to any of the excipients
- •Pregnancy and lactation
- •Biliary obstructive disorders
- •Severe hepatic impairment
- •Severe renal impairment
研究组 & 干预措施
Outpatients with essential hypertension
干预措施: Low dose of Telmisartan, once daily (Drug)
Outpatients with essential hypertension
干预措施: High dose of Telmisartan, once daily (Drug)
结局指标
主要结局
Global evaluation of treatment compliance by investigator, a 6-point rating scale
时间窗: 4 weeks and 3 months after start of treatment
Changes in systolic and diastolic blood pressure
时间窗: Baseline, 4 weeks and 3 months after start of treatment
Percentage of patients with dose titration to 80 mg
时间窗: 4 weeks and 3 months after start of treatment
Number of patients with adverse events
时间窗: Up to 3 months after start of treatment
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in HospitalsHypertensionNCT02238262Boehringer Ingelheim2,318
已完成
不适用
Micardis® in Patients With Essential HypertensionHypertensionNCT02187705Boehringer Ingelheim1,688
已完成
不适用
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential HypertensionHypertensionNCT02176850Boehringer Ingelheim19,870
已完成
不适用
Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With HypertensionHypertensionNCT02242357Boehringer Ingelheim14,553
已完成
不适用
Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes MellitusHypertensionNCT02242825Boehringer Ingelheim8,148